MiRXES announced today that Dr. Lihan ZHOU, Co-founder and Chief Executive Officer at MiRXES, Dr. Ruiyang ZOU, Co-founder and Chief Technology Officer at MiRXES and Mr. Isaac HO, Chief Investment Officer at MiRXES, have been named EY Entrepreneur Of The Year (EOY) 2021 Singapore by professional services organization, EY.
At-home cancer tests that could detect the disease even in the absence of symptoms? They could very well be a possibility in the future.
Dr Zhou is the Chief Executive Officer of MiRXES, a biotechnology company he co-founded with Chief Technology Officer Dr Zou Ruiyang, that specialises in producing polymerase chain reaction (PCR) tests to detect early stage cancer. The company brings to life his vision, running with the ethos that prevention is better than cure, and that early detection enables early interception, leading to early treatment and subsequently, saved and improved lives.
Whenever we fall sick, we often associate each illness with a characteristic set of symptoms. Constantly sneezing with a bad rash? Must be allergies. Stuffy nose and sore throat? Likely the flu. Bloodshot eyes? Likely conjunctivitis or pink eye. But not all diseases come with obvious symptoms.
At MiRXES, we harness the power of RNA to deliver early, actionable and personalized diagnoses across the care continuum to improve and save lives. Prevention is better than cure.
With early detection, mitigating risk factors and implementing prevention strategies, most cancer deaths can be prevented.
Our science opens us to a world without late-stage cancer diagnoses. This is how we improve and save lives.
MiRXES endeavors to be at the forefront of disease early detection and interception.
One in four people has cancer in the world today. At MiRXES, we know the importance of science in the fight against cancer.
We understand that to make the most impact in improving and saving lives, we must translate and deliver our innovative solutions from the lab to clinic.
Read more about how our solutions that range from industry-leading discovery tools and services to diagnostic tests for cancer, cardiovascular, metabolic and infectious diseases, and precision oncology can enable you to act sooner – when it matters most.